Correction of human mucopolysaccharidosis type-VI fibroblasts with recombinant N-acetylgalactosamine-4-sulphatase.
about
Expression, purification and characterization of recombinant human N-acetylgalactosamine-6-sulphataseRecombinant human sulphamidase: expression, amplification, purification and characterizationArylsulfatase B improves locomotor function after mouse spinal cord injuryIdentification of mutations in the alpha-L-iduronidase gene (IDUA) that cause Hurler and Scheie syndromesTwo site-directed mutations abrogate enzyme activity but have different effects on the conformation and cellular content of the N-acetylgalactosamine 4-sulphatase proteinHigh-level production of recombinant human lysosomal acid alpha-glucosidase in Chinese hamster ovary cells which targets to heart muscle and corrects glycogen accumulation in fibroblasts from patients with Pompe diseaseIdentification, expression, and biochemical characterization of N-acetylgalactosamine-4-sulfatase mutations and relationship with clinical phenotype in MPS-VI patientsSulfatases: structure, mechanism, biological activity, inhibition, and synthetic utility.Carbohydrate structures of recombinant human alpha-L-iduronidase secreted by Chinese hamster ovary cells.Enzyme replacement therapy in a feline model of Maroteaux-Lamy syndrome.Arylsulfatase B activities and glycosaminoglycan levels in retrovirally transduced mucopolysaccharidosis type VI cells. Prospects for gene therapy.Microbial alkyl- and aryl-sulfatases: mechanism, occurrence, screening and stereoselectivities.A Pro504 --> Ser substitution in the beta-subunit of beta-hexosaminidase A inhibits alpha-subunit hydrolysis of GM2 ganglioside, resulting in chronic Sandhoff disease.Lysosomal enzyme replacement therapies: Historical development, clinical outcomes, and future perspectives.Identification and molecular characterization of alpha-L-iduronidase mutations present in mucopolysaccharidosis type I patients undergoing enzyme replacement therapy.Mutational analysis of mucopolysaccharidosis type VI patients undergoing a trial of enzyme replacement therapy.Immortalization and characterization of a cell line exhibiting a severe multiple sulphatase deficiency phenotype.Isolation and characterisation of a recombinant, precursor form of lysosomal acid alpha-glucosidase.Recombinant alpha-L-iduronidase: characterization of the purified enzyme and correction of mucopolysaccharidosis type I fibroblasts.Recombinant human iduronate-2-sulphatase: correction of mucopolysaccharidosis-type II fibroblasts and characterization of the purified enzyme.Comparison of HCMV IE and EF-1 promoters for the stable expression of beta-subunit of hexosaminidase in CHO cell lines.Expression, purification and characterization of recombinant caprine N-acetylglucosamine-6-sulphatase.Chondroitin sulfatases differentially regulate Wnt signaling in prostate stem cells through effects on SHP2, phospho-ERK1/2, and Dickkopf Wnt signaling pathway inhibitor (DKK3).Galsulfase.Enzyme replacement therapy improves joint motion and outcome of the 12-min walk test in a mucopolysaccharidosis type VI patient previously treated with bone marrow transplantation.Mild feline mucopolysaccharidosis type VI. Identification of an N-acetylgalactosamine-4-sulfatase mutation causing instability and increased specific activity.Decline in Arylsulfatase B Expression Increases EGFR Expression by Inhibiting the Protein Tyrosine Phosphatase SHP2 and Activating JNK in Prostate Cells.
P2860
Q24528221-3B41E76A-E453-46C7-8DF3-CB54AA8FDCB0Q24530626-FF738108-63B3-48F9-8427-C159C32E51C1Q27313217-1FA9D620-D2EF-4DB4-A4F4-02938B9AF21BQ28609285-E47E1AD3-6D8C-4F2F-A7B9-9A7AE67A0AE4Q30418311-FEDBB794-D103-4776-8037-17143FB01783Q33598299-E4DE2F44-0FE2-4780-9480-76798E2362C8Q35882767-90A3A1B5-EF35-4183-9175-5B37CF01AD63Q35922289-090CA8FC-8680-4D79-AB60-DA2F8C2AF19FQ36879990-D0C79443-E56F-4C1A-ACEF-8CB1CBCAEBD3Q37354249-BB1269DA-648C-46D3-9791-C47322FD06F7Q37357839-B28020DE-0B76-408C-A24C-EF1989A5705EQ38172428-1AB571AB-C082-4F7E-AB95-21650336FAB1Q38334617-91E2746D-469A-41E9-A6BA-04A662132A2FQ38684097-EFAD52EA-ED3B-4E3E-BE26-5B91554DA29DQ40527301-F91C1AED-72B2-4090-8C43-C1DAA3B63410Q40587905-4F3FEA5C-5BF4-4343-8A69-A7534E2957C7Q41093678-365469ED-B06D-4289-8FB6-94E0F4FE818FQ41258978-F8D699CF-AE0D-43CF-86E7-1ABE57C6CC74Q41428678-8FC8BAD1-E03E-4702-80B3-AC097DBCCBEBQ41581384-63CAD653-630D-43B3-AA9D-7461BF613D5DQ42155604-1439DBDB-FFE9-4F41-9852-B80A5702AE03Q42987957-77D6AA46-DA4F-4CFE-A89C-2372FDA1D39EQ47170567-EDB4433F-F3B3-403B-B141-E0DB92E90EAFQ51809648-618DCA14-D8AB-49AC-8CE8-0E32A6619C26Q53380756-58B46A77-6FF9-4D86-9E78-5C12E89EA9CEQ54709909-15B23AAC-B51E-4A64-A445-F6BD9FF05B23Q54978374-642D4BE0-5147-439F-9466-8BBA54DDE3FA
P2860
Correction of human mucopolysaccharidosis type-VI fibroblasts with recombinant N-acetylgalactosamine-4-sulphatase.
description
1992 nî lūn-bûn
@nan
1992年の論文
@ja
1992年学术文章
@wuu
1992年学术文章
@zh-cn
1992年学术文章
@zh-hans
1992年学术文章
@zh-my
1992年学术文章
@zh-sg
1992年學術文章
@yue
1992年學術文章
@zh
1992年學術文章
@zh-hant
name
Correction of human mucopolysa ...... tylgalactosamine-4-sulphatase.
@en
type
label
Correction of human mucopolysa ...... tylgalactosamine-4-sulphatase.
@en
prefLabel
Correction of human mucopolysa ...... tylgalactosamine-4-sulphatase.
@en
P2093
P2860
P356
P1433
P1476
Correction of human mucopolysa ...... tylgalactosamine-4-sulphatase.
@en
P2093
Bielicki J
Hopwood JJ
P2860
P304
P356
10.1042/BJ2840789
P407
P478
284 ( Pt 3)
P577
1992-06-01T00:00:00Z